FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085756615> ?p ?o ?g. }

• W2085756615 endingPage "1012" @default.
• W2085756615 startingPage "1003" @default.
• W2085756615 abstract "Abstract Urinary prothrombin fragment 1 (UPTF1) is the principal protein in calcium oxalate (CaOx) crystals precipitated from human urine and is a potent inhibitor of CaOx crystallization, a property that should depend, at least in part, upon the extent of γ‐carboxylation of the 10 glutamic residues in its N–terminal region. Warfarin therapy limits full γ‐carboxylation of vitamin K–dependent proteins, including UPTF1. The aims of this study were to determine the effect of warfarin therapy on UPTF1, its occlusion into CaOx urinary crystals, and its influence on the crystallization of CaOx in undiluted human urine. In the first part of the study, urines were collected from six men prior to cardiac surgery and after stabilization on long‐term warfarin treatment. Proteins in the urines and in the matrix of CaOx crystals precipitated from them were analyzed by two‐dimensional SDS‐PAGE and Western blotting. In urine, at least two charge variants of UPTF1 with low isoelectric point (pI) values were detected before and during warfarin therapy, but additional higher pI forms of the protein were also seen during anticoagulation. Nonetheless, the majority of UPTF1 was present in the more fully γ‐carboxylated state. CaOx crystals precipitated from the same urine samples contained only low pI forms of UPTF1. The effect of warfarin treatment on CaOx crystallization in urine was tested by collecting two consecutive 24‐h urine samples from 16 men prior to cardiac surgery and during subsequent warfarin treatment. CaOx crystallization was induced in each sample by the addition of sodium oxalate. The size and volume of the particles deposited were determined using a Coulter counter, and the crystals were examined by scanning electron microscopy (SEM). There were no significant differences between the urinary metastable limits before or during warfarin treatment or in the total volume of crystals precipitated. A slight increase in the mean diameter of the crystalline particles precipitated from the urines during anticoagulant therapy was not significant. SEM showed little evidence of changes in overall particle size, although individual crystals of CaOx tended to be larger during warfarin treatment. It was concluded from these studies that the binding of UPTF1 to CaOx crystal surfaces is related to the degree of γ‐carboxylation of its Gla domain, which would also influence the protein's inhibitory effects on CaOx crystallization. However, during warfarin therapy the majority of UPTF1 exists in a highly charged state, indicating that it is completely, or almost completely, γ‐carboxylated, which would explain the lack of any difference between CaOx crystallization parameters in the urine of subjects before and during warfarin administration. We conclude that physiologically significant reductions in the inhibitory potency of UPTF1 would be likely to occur only as a result of proscription of γ‐carboxylation more extensive than that induced by warfarin." @default.
• W2085756615 created "2016-06-24" @default.
• W2085756615 creator A5000934592 @default.
• W2085756615 creator A5012662598 @default.
• W2085756615 creator A5030175709 @default.
• W2085756615 creator A5067772621 @default.
• W2085756615 creator A5069356109 @default.
• W2085756615 date "1999-06-01" @default.
• W2085756615 modified "2023-10-10" @default.
• W2085756615 title "The Effect of Warfarin Therapy on the Charge Properties of Urinary Prothrombin Fragment 1 and Crystallization of Calcium Oxalate in Undiluted Human Urine" @default.
• W2085756615 cites W1448845429 @default.
• W2085756615 cites W1509083776 @default.
• W2085756615 cites W1559610250 @default.
• W2085756615 cites W1581434042 @default.
• W2085756615 cites W1594886297 @default.
• W2085756615 cites W1601174174 @default.
• W2085756615 cites W1970516721 @default.
• W2085756615 cites W1984651358 @default.
• W2085756615 cites W1985776013 @default.
• W2085756615 cites W1995067217 @default.
• W2085756615 cites W2015699513 @default.
• W2085756615 cites W2021312394 @default.
• W2085756615 cites W2029279116 @default.
• W2085756615 cites W2029528282 @default.
• W2085756615 cites W2052737936 @default.
• W2085756615 cites W2075206292 @default.
• W2085756615 cites W2076327477 @default.
• W2085756615 cites W2076820940 @default.
• W2085756615 cites W2082106501 @default.
• W2085756615 cites W2101108802 @default.
• W2085756615 cites W2126308020 @default.
• W2085756615 cites W2161593640 @default.
• W2085756615 cites W2313774959 @default.
• W2085756615 cites W2399648275 @default.
• W2085756615 cites W2408648708 @default.
• W2085756615 cites W2408808838 @default.
• W2085756615 cites W2422957279 @default.
• W2085756615 cites W2440027873 @default.
• W2085756615 cites W2441544974 @default.
• W2085756615 cites W267094029 @default.
• W2085756615 cites W2807578326 @default.
• W2085756615 doi "https://doi.org/10.1359/jbmr.1999.14.6.1003" @default.
• W2085756615 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10352110" @default.
• W2085756615 hasPublicationYear "1999" @default.
• W2085756615 type Work @default.
• W2085756615 sameAs 2085756615 @default.
• W2085756615 citedByCount "13" @default.
• W2085756615 countsByYear W20857566152019 @default.
• W2085756615 countsByYear W20857566152021 @default.
• W2085756615 crossrefType "journal-article" @default.
• W2085756615 hasAuthorship W2085756615A5000934592 @default.
• W2085756615 hasAuthorship W2085756615A5012662598 @default.
• W2085756615 hasAuthorship W2085756615A5030175709 @default.
• W2085756615 hasAuthorship W2085756615A5067772621 @default.
• W2085756615 hasAuthorship W2085756615A5069356109 @default.
• W2085756615 hasBestOaLocation W20857566151 @default.
• W2085756615 hasConcept C126322002 @default.
• W2085756615 hasConcept C178790620 @default.
• W2085756615 hasConcept C179104552 @default.
• W2085756615 hasConcept C185592680 @default.
• W2085756615 hasConcept C203036418 @default.
• W2085756615 hasConcept C2776179656 @default.
• W2085756615 hasConcept C2776301958 @default.
• W2085756615 hasConcept C2776351790 @default.
• W2085756615 hasConcept C2779161974 @default.
• W2085756615 hasConcept C2780026642 @default.
• W2085756615 hasConcept C43617362 @default.
• W2085756615 hasConcept C519063684 @default.
• W2085756615 hasConcept C55493867 @default.
• W2085756615 hasConcept C71924100 @default.
• W2085756615 hasConcept C77411442 @default.
• W2085756615 hasConcept C98274493 @default.
• W2085756615 hasConceptScore W2085756615C126322002 @default.
• W2085756615 hasConceptScore W2085756615C178790620 @default.
• W2085756615 hasConceptScore W2085756615C179104552 @default.
• W2085756615 hasConceptScore W2085756615C185592680 @default.
• W2085756615 hasConceptScore W2085756615C203036418 @default.
• W2085756615 hasConceptScore W2085756615C2776179656 @default.
• W2085756615 hasConceptScore W2085756615C2776301958 @default.
• W2085756615 hasConceptScore W2085756615C2776351790 @default.
• W2085756615 hasConceptScore W2085756615C2779161974 @default.
• W2085756615 hasConceptScore W2085756615C2780026642 @default.
• W2085756615 hasConceptScore W2085756615C43617362 @default.
• W2085756615 hasConceptScore W2085756615C519063684 @default.
• W2085756615 hasConceptScore W2085756615C55493867 @default.
• W2085756615 hasConceptScore W2085756615C71924100 @default.
• W2085756615 hasConceptScore W2085756615C77411442 @default.
• W2085756615 hasConceptScore W2085756615C98274493 @default.
• W2085756615 hasIssue "6" @default.
• W2085756615 hasLocation W20857566151 @default.
• W2085756615 hasLocation W20857566152 @default.
• W2085756615 hasOpenAccess W2085756615 @default.
• W2085756615 hasPrimaryLocation W20857566151 @default.
• W2085756615 hasRelatedWork W105971956 @default.
• W2085756615 hasRelatedWork W1508049235 @default.
• W2085756615 hasRelatedWork W1999661533 @default.
• W2085756615 hasRelatedWork W2031256360 @default.
• W2085756615 hasRelatedWork W2058832365 @default.

• next